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Introduction
Prostate cancer has become one of the leading lethal cancers in
males in many Western industrialized countries, despite progress
in diagnosis and treatment. Once tumour cells have spread beyond
the tissue capsule or metastasized to local lymph nodes and distal
organs, therapy is limited. The genesis of cancer, malignant
growth and dissemination of tumour cells are, at least in part,
based on the up-regulation of histone deacetylases (HDACs),
leading to distinct modifications of histone proteins and silencing
of gene expression. Prostate cancer studies have demonstrated
that HDAC activity is enhanced in pre-malignant and malignant
lesions, with the highest increase in expression in hormone refrac-
tory cancer [1]. In vitro analysis of prostate tumour cell lines has
revealed cell proliferation and differentiation to be significantly
dependent on HDAC overexpression [2]. Therefore, HDAC-inhibi-
tion offers an appropriate target for inducing tumour-blocking
mechanisms and, consequently, compounds which suppress
HDACs may serve as potential antitumoural drugs to treat prostate
cancer. 
The short-chain fatty acid valproic acid (VPA) has been used
for decades in the treatment of seizure disorders in children and
adults with minimal side effects but emerged in 1997 as an 
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Abstract
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory proper-
ties. However, the effects of valproic acid (VPA) are limited and concentrations required for exerting anti-neoplastic effects in vitro may
not be reached in tumour patients. In this study, we tested in vitro and in vivo effects of two VPA-derivatives (ACS2, ACS33) on pre-clin-
ical prostate cancer models. PC3 and DU-145 prostate tumour cell lines were treated with various concentrations of ACS2 or ACS33 to
perform in vitro cell proliferation 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and to evaluate tumour cell
adhesion to endothelial cell monolayers. Analysis of acetylated histones H3 and H4 protein expression was performed by western blot-
ting. In vivo tumour growth was conducted in subcutaneous xenograft mouse models. Tumour sections were assessed by immunohis-
tochemistry for histone H3 acetylation and proliferation. ACS2 and ACS33 significantly up-regulated histone H3 and H4 acetylation in
prostate cancer cell lines. In micromolar concentrations both compounds exerted growth arrest in PC3 and DU-145 cells and prevented
tumour cell attachment to endothelium. In vivo, ACS33 inhibited the growth of PC3 in subcutaneous xenografts. Immunohistochemistry
and western blotting confirmed increased histone H3 acetylation and reduced proliferation. ACS2 and ACS33 represent novel VPA deriv-
atives with superior anti-tumoural activities, compared to the mother compound. This investigation lends support to the clinical testing
of ACS2 or ACS33 for the treatment of prostate cancer.
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anti-neoplastic agent as well, when findings indicated that the sub-
stance inhibited proliferation and induced differentiation of primi-
tive neuroectodermal tumour cells in vitro and in vivo [3]. The
anti-cancer characteristics of VPA has meanwhile been investi-
gated in pre-clinical models of skin, breast, colon, prostate and
small cell lung cancer. Currently, the drug is in phase I trials [4, 5].
It is now recognized that VPA evoked modulations of tumour cell
biology (which not only include cell growth and differentiation, but
also metastatic and angiogenetic potency) are mediated by HDAC-
inhibition [6, 7]. VPA may, therefore, represent an anti-tumoural
compound with great pharmaceutical potential. In fact, among a
growing list of HDAC-inhibitors, VPA provides several advantages.
It is well tolerated, exhibits low toxicity in adults and, with a half-
life of 16–17 hrs, has suitable pharmacokinetic properties in vivo
[8]. However, effective VPA-concentrations used in in vitro culture
models are in the range of 1-5 mM; whereas, due to high-plasma
protein binding of the drug, the free, active VPA-levels obtained in
patients with epilepsy are in the range of 50–200  M. Therefore,
the differences between desirable and therapeutically achievable
plasma concentrations of VPA may limit its application. With
respect to this obstacle, evidence has recently been presented that
slight changes in the molecular structure of VPA substantially
enhance its efficacy, without influencing the pharmacokinetic
properties of the drug [9, 10]. Based on these experiments, we
speculated that VPA-derivatives may allow drug application in a
lower concentration range. 
Organosulphur compounds including allyl isothiocyanate have
previously been shown to cause increased acetylation of histones
and differentiation in mouse erythroleukaemia cells [11]. In addi-
tion, the isothiocyanate sulforaphane has just been identified as an
anti-carcinogen that acts on human colon and prostate cancer
cells through HDAC-inhibition [12]. Dithiolethiones, like oltipraz
(5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione) or anethole
trithione (5-(4-methoxyphenyl)-1,2-dithiole-3-thione) are known
to exert anti-cancer effects and angiostatic activity [13–15], and 
S-methyl methanethiosulfonate, isolated from cauliflower, has been
demonstrated to inhibit colon tumour incidence when adminis-
tered to rats during the post initiation phase of carcinogenesis
[16]. The findings prompted us to prepare hybrids of VPA with dif-
ferent organosulphur moieties. Of these, 2-propyl-pentanoic acid
4-(3H-1,2-dithiole-3-thione-5-yl)-phenyl ester (ACS2), an ester of
VPA with 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione, potently
inhibited endothelial cell proliferation and angiogenic responses in
muscle and HT29 tumour explants assessed by 3-dimensional
collagen matrix assays [17]. To explore if VPA-hybrids may be
qualified to treat prostate cancer, we analysed the influence of
ACS2 and of another VPA-derivative, 2-propyl-  pentanoic acid 
2-methanesulfonylsulfanyl-ethyl ester (ACS33), on prostate tumour
cells in vitro and in vivo.
Our data show that both compounds are active in the  m
range. Growth capacity as well as adhesion of PC3 or DU-145
prostate tumour cell lines to endothelium was significantly pre-
ventable at concentrations of 30  M (ACS2) or 7  M (ACS33).
The effects were accompanied by a distinct increase of histone H3
and H4 acetylation. The prostate tumour xenograft volume was
diminished by 70% under ACS33 treatment, and enhanced histone
H3 acetylation together with reduced mitosis was found in the
tumour tissue. The findings suggest that VPA-derivatives may be
of potential therapeutic benefit in the treatment of prostate cancer.
Materials and methods
Cell cultures
Human endothelial cells (HUVEC) were isolated from human umbilical
veins and harvested by enzymatic treatment with chymotrypsin. HUVEC
were grown in Medium 199 (M199; Biozol, Munich, Germany), supple-
mented with 10% foetal calf serum (FCS), 10% pooled human serum, 20
 g/ml endothelial cell growth factor (Boehringer, Mannheim, Germany),
0.1% heparin, 100 ng/ml gentamycin and 20 mM HEPES-buffer (pH 7.4).
Subcultures from passages 2–6 were selected for experimental use.
Human prostate tumour cell lines PC3 and DU-145 were obtained from
DSMZ (Braunschweig, Germany). Tumour cells were grown and subcul-
tured in RPMI 1640 (Gibco/Invitrogen; Karlsruhe, Germany). The medium
contained 10%  FCS, 2% HEPES-buffer (1M, pH 7.4), 2% glutamine and
1% penicillin/streptomycin. Subcultures from passages 7–11 were
selected for experimental use. Cell viability was determined by trypan blue
(Gibco/Invitrogen, Karlsruhe, Germany). All cells were maintained in a
37°C incubator in a 5% CO2 humidified atmosphere.
ACS2 and ACS33
ACS2 [17] and ACS 33 [18] were supplied by Sulfidris s.r.l., Milano, Italy
(Fig. 1). Both compounds were used in different concentrations and for dif-
ferent time periods, as indicated in results. 
Tumour cell growth
Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) dye reduction assay (Roche
Diagnostics, Penzberg, Germany). DU-145 or PC-3 (100  l, 1   10
4
cells/ml) were seeded onto 96-well tissue culture plates and incubated as
described above. After 24 hrs, MTT (0.5 mg/ml) was added for an addi-
tional 4 hr. Thereafter, cells were lysed in a buffer containing 10% SDS in
0.01 M HCl. The plates were allowed to stand overnight at 37°C, 5% CO2.
Absorbance at 570 nm was determined for each well using a microplate
ELISA reader. Each experiment was done in triplicate. After subtracting
background absorbance, results were expressed as mean cell number.
Tumour cell adhesion to HUVEC
HUVEC were transferred to 6-well multiplates (Falcon Primaria; BD
Biosciences, Heidelberg, Germany) in complete HUVEC-medium. When
confluency was reached, PC3 or DU-145 cells were detached from the cul-
ture flasks by accutase treatment (PAA Laboratories, Cölbe, Germany) and
0.5   10
6 cells were then added to the HUVEC monolayer for 60 min.
Subsequently, non-adherent tumour cells were washed off using warmed
(37°C) Medium 199. The remaining cells were fixed with 1% glutaraldehyde.
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In each experimental setting, adherent tumour cells were counted in five
different fields of a defined size (5   0.25 mm
2) using a phase contrast
microscope and the mean cellular adhesion rate was calculated. 
Western blotting
Acetylated histones H3 and H4 in PC3, DU-145 tumour cells, or in frozen
tissue specimens generated from nude mice xenografts, were evaluated by
western blot analysis. Tumour cell lysates were applied to a 7% polyacry-
lamide gel and electrophoresed for 90 min. at 100 V. The protein was then
transferred to nitrocellulose membranes. After blocking with non-fat dry
milk for 1 hr, the membranes were incubated overnight with the antibodies
for histone H3 (rabbit monoclonal IgG, clone Y173, dilution 1:5.000), acety-
lated H3 (rabbit monoclonal IgG, clone Y28, dilution 1:500), histone H4
(rabbit polyclonal IgG, dilution 1:250) or acetylated H4 (Lys8, rabbit poly-
clonal IgG, dilution 1:500; all: Biomol GmbH, Hamburg, Germany). In the
second part of the experiments, beta1 integrins as well as apoptotic and 
differentiation markers were analysed: anti- 1 integrins (IgG1, clone MAR4,
dilution 1:2500), anti-integrin-linked kinase (ILK; clone 3, dilution 1:1000),
anti-focal adhesion kinase (Fak, clone 77, dilution 1:1000), anti-phospho-
specific Fak (pY397, clone 18, dilution 1:1000) were all from BD
Biosciences. Bax (IgG, polyclonal, dilution 1:200) and bcl-2 (IgG, polyclonal,
dilution 1:200) were from Santa Cruz Biotechnology, Heidelberg, Germany.
HRP-conjugated goat-antimouse IgG (Upstate Biotechnology, Lake Placid,
NY, USA; dilution 1:5000) served as the secondary antibody. The mem-
branes were briefly incubated with ECL detection reagent (ECL
TM,
Amersham/GE Healthcare, München, Germany) to visualize the proteins and
exposed to an x-ray-film (Hyperfilm
TM EC
TM, Amersham/GE Healthcare). 
 -actin (1:1.000) served as the internal control.
Tumour growth in vivo
For in vivo testing, 10
7 PC3 cells were injected s.c. to male NMRI:nu/nu
mice (EPO GmbH, Berlin, Germany). Treatment was initiated when tumours
had grown to a palpable size (5-6 mm diameter). ACS33 was dissolved in
10% polyethylene glycol (PEG) 400/saline. It was injected i.p. in doses of
20 mg/kg/day once daily. One group of mice was treated with the solvent
(negative control, n = 10) and another group with cisplatin (Medac,
Hamburg, Germany; n = 8) at a dose of 2 mg/kg/day, i.e. at a dose that was
determined to be of significant efficacy in other xenograft experiments
(unpublished). Tumour size was measured with calipers. Tumour volumes,
relative tumour volumes (relative to the first treatment day) and
treated/control (T/C) values were calculated. Body weight and mortality
were recorded continuously to estimate tolerability. 
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumour sections (1.5  m thickness)
were deparaffinized according to established procedures and stained
with haematoxylin and eosin or immunostained by indirect immunoper-
oxidase method (DAKO), as recommended by the manufacturer. For
immunostaining, the MIB monoclonal mouse (Dako, M724001) and the
anti acetyl histone H3 monoclonal rabbit (Biomol, 1328-1) antibodies
were used at dilutions of 1:200 and 1:100, respectively. The sections
were examined by a pathologist and one additional independent investi-
gator trained in the histopathology of the tumours.
Statistical analysis
All studies were performed three to six times. Statistical significance was
investigated by the Wilcoxon-Mann-Whitney-U-test. Differences were con-
sidered statistically significant at a P-value less than 0.05.
Results
ACS2 and ACS33 down-regulate 
in vitro cell growth
Cell proliferation of DU-145 and PC3 cells was quantified 24 hrs
and 48 hrs after plating. To clearly interpret and compare the
growth characteristics of treated versus untreated tumour cells,
24 hrs counts were all set at 100%. Based on this, the number of
untreated DU-145 cells as control increased in the ACS2 study
from 100% (2799   186 cells/well) to 160% (Fig. 2A, left) or
155% (Fig. 2A, right), and in the ACS33 study from 100% (2679  
302 cells/well) to 172% (Fig. 2B, left) or 166% (Fig. 2B, right).
PC3 control cells increased in the ACS2 study from 100% (2553  
161 cells/well) to 178% (Fig. 2A, left) or 169% (Fig. 2A, right), and
in the ACS33 study from 100% (2448   296 cells/well) to 190%
(Fig. 2B, left) or 177% (Fig. 2B, right). According to earlier obser-
vations, simultaneous addition of ACS2 or ACS33 into the multi-
well plates did not influence the growth characteristics of DU-145
and PC3 cell lines. However, a pre-incubation for 3 days with ACS2
(prior to plating the cells in multi-well plates for 24 or 48 hrs) at
concentrations  30  M significantly blocked the proliferation of
both DU-145 and PC3 cells (Fig. 2A). The anti-proliferative effects
of ACS2 were even more pronounced when tumour cells were
pre-treated with the compound for 5 days and then added into
multi-well plates for another 24 or 48 hrs. Already, 15  M 
(DU-145) or 7  M (PC3) were then sufficient to reduce the growth
capacity significantly, compared to the controls. 
Fig. 1 Chemical structures of histone deacetylase (HDAC)-inhibitors
ACS2 and ACS33.2460 © 2008 The Authors
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Fig. 2 Effects of ACS2 (2A) or ACS33 (2B) on prostate cancer proliferation in vitro. DU-145 or PC3 cells were treated with various concentrations 
of ACS2 or ACS33 for 3 or 5 days, or remained un-treated (control). Cell proliferation was then assessed using the MTT dye reduction assay. Cell
numbers at day 2 (48 hrs) were normalized to the number of day 1 (24 hrs, as 100%). One representative of six experiments is shown. * indicates
significant difference to controls.J. Cell. Mol. Med. Vol 12, No 6A, 2008
2461 © 2008 The Authors
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Stronger anti-proliferative effects were noted with respect to
ACS33. 15  M (DU-145) or 7  M (PC3), applied for 3 days, were
sufficient to completely block tumour cell growth (Fig. 2B). In con-
trast to ACS2, extension of the pre-incubation period to 5 days 
did not further enhance the anti-tumoural potential of ACS33. 
In all experiments, the drugs were maintained before transfer-
ring the tumour cells into multi-well plates and during the 24 and
48 hrs cell growth evaluation period.
ACS2 and ACS33 block tumour cell adhesion 
to endothelium
The number of adherent DU-145 control cells rapidly increased
and reached a plateau after 2 hrs (1 hr control values were as fol-
lows: ACS2 study: 66.4   6.0 cells/mm
2 in the 3 day incubation
protocol; 98.4   8.8 cells/mm
2 in the 5 day incubation protocol.
ACS33 study: 42.2   7.6 cells/mm
2 in the 3 day incubation pro-
tocol; 86.1   14.9 cells/mm
2 in the 5 day incubation protocol).
PC3 control cell adhesion steadily increased up to 4 hrs (1 hr con-
trol values were as follows: ACS2 study: 69.2   8.0 cells/mm
2 in
the 3 day incubation protocol; 80.8   11.8 cells/mm
2 in the 5 day
incubation protocol. ACS33 study: 68.0   12.6 cells/mm
2 in the 
3 day incubation protocol; 101.2   19.7 cells/mm
2 in the 5 day
incubation protocol), and significantly more PC3 cells attached to
HUVEC than DU-145 cells (Fig. 3A and B). Similar to the growth
blocking effects, a 3 day ACS2 pre-incubation at concentrations
 30  m significantly decreased (but did not completely prevent)
adhesion of both DU-145 and PC3 cells to HUVEC. A 5 day pre-
incubation further enhanced the adhesion-blocking effects of
ACS2, resulting in very flat adherence curves (Fig. 3A).
ACS33 exerted stronger effects on both tumour cell lines than
did ACS2. This was demonstrated by ACS33 concentrations <30  M
being sufficient to significantly decrease PC3 or DU-145 attach-
ment to HUVEC (Fig. 3B). Interestingly, pre-incubating the cells for
5 days with ACS33 did not lead to a more pronounced reduction
of tumour cell adhesion and flat adherence curves seen with
ACS2. Notably, the effect of ACS33 on PC3 cells was even slightly
diminished when the drug was applied after 5 days, compared to
the 3 day incubation period. 
Figure 4 demonstrates the influence of ACS33 on the endothelial
integrity. In all co-culture experiments carried out with DU-145 or
PC3 round openings in the endothelial monolayer in the course of
tumour cell binding, due to focal disruptions of intercellular endothe-
lial connections, were observed. Treatment of DU-145 or PC3 cells
with ACS33 not only prevented tumour cell adhesion, as described
above, but also prevented disruption of the HUVEC monolayer.
Similar effects were also seen with respect to ACS2 (data not shown).
ACS2 and ACS33 increase histone 
H3 and H4 acetylation
DU-145 or PC3 cells were treated with ACS2 or ACS33 for 24 hrs
and then histone acetylation was assessed by western blot. Both
cell lines showed distinct increases in acetylated H3 and H4 under
drug treatment (Fig. 5). Modifications of acetylated H4 became evi-
dent at concentrations  15  M independent with both ACS2 or
ACS33 application. H3 acetylation strongly increased in presence
of 30  M ACS2 or ACS33, however, slight effects on H3 acetylation
were also seen when ACS2 was applied at 15  M. 
ACS33 treatment inhibits progression 
of tumour xenografts
Based on our in vitro data, ACS33 exerted higher adhesion and
growth-blocking properties than did ACS2. We, therefore, estab-
lished tumour xenografts in athymic nu/nu mice using PC3 cells to
evaluate the effects of ACS33 on prostate cancer cell growth 
in vivo. Animals in the treatment arm received ACS33 at a dose of
20 mg/kg body weight daily. Compared to the untreated animals,
application of ACS33 significantly diminished the tumour volume,
with reductions of 75% (day 17, day 24) and 60% (day 20), com-
pared to the control (Fig. 6). No body weight loss or diarrhea was
observed and all animals (treated as well as non-treated) kept alive.
Western blot analysis revealed increased histone H3 and H4 acety-
lation in tissue specimens of treated animals (Fig. 6, right).
Furthermore, bcl-2 was down-regulated whereas bax was
enhanced, compared to the controls. No differences were seen with
respect to integrin  1 adhesion receptors and ILK expression.
However, Fak and phosphorylated Fak became strongly reduced in
tissue specimens of animals treated with ACS33 (Fig. 6, right).
Immunohistochemistry with antibodies against H3 acetylation
demonstrated intense nuclear staining in tumour cells derived from
ACS33-treated animals, whereas the immunoreactivity for the pro-
liferation marker MIB was diminished remarkably (Fig. 7). 
Discussion
Several studies have pointed to the important role the HDAC-
inhibitor, VPA, may play in treating prostate cancer. VPA not only
down-regulates prostate-specific antigen to basal levels in LNCaP
cells, but also mediates the expression of genes relevant to
tumour proliferation and apoptosis [19, 20]. Angiogenesis and
senescence in prostate tumour cells have also been shown to be
influenced by VPA [21]. The bone-invasive potential of prostate cancer
in mice is impaired by VPA [22] and appears particularly effective
in controlling refractory stages of this disease [23]. 
The advantages of VPA include low cost, favourable safety pro-
file and oral dosing. However, the plasma trough concentrations
obtained in patients by common anti-epileptic dose regimens are
below the concentration required for anti-tumour effects in vitro.
It is still not clear if adaptation of the dosing schedule to the anti-
cancer protocol can be carried out with acceptable toxicity [24].
Indeed, dose-limiting toxicities as neurological impairment and
febrile neutropenia have been observed in phase I studies [4, 5].2462 © 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 Adhesion of prostate cancer cells to human endothelial cells (HUVEC) is down-regulated by ACS2 (3A) or ACS33 (3B). DU-145 or PC3 cells were
treated with various concentrations of ACS2 or ACS33 for 3 or 5 days, and then added at a density of 0.5   10
6 cells/well to HUVEC monolayers for
different time periods. Non-adherent tumour cells were washed off in each sample; the remaining cells were fixed and counted in five different fields
(5   0.25 mm
2) using a phase contrast microscope. Mean values were calculated from five counts. Mean adhesion capacity is depicted as counted
cells/mm
2. One representative of six experiments is shown. * Indicates significant difference to controls.J. Cell. Mol. Med. Vol 12, No 6A, 2008
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VPA has also been associated with reversible hepatotoxicity and,
in few cases, with lethal hepatopathies [25]. 
Circumvention of the dosage problem can be achieved by
structurally modifying VPA. Some of these derivatives exceed 
the HDAC-inhibition potential 40-fold, compared to the mother
compound [9]. 
In this investigation, we report the development of a novel class
of HDAC inhibitors, in which VPA was tethered to 5-(4-hydrox-
yphenyl)-3H-1,2-dithiole-3-thione, or to 2-hydroxyethyl methane-
thiosulfonate, both sulfurated moieties through an ester linkage.
This structural optimization was based on the hypothesis that
inserting an organosulphur group can improve HDAC inhibition. It
has previously been shown that several organosulphur com-
pounds inhibit cell proliferation and HDAC, possibly by epigeneti-
cally priming cells to respond more effectively to external insults
such as oxidative stress or toxins [12].
In fact, treatment of DU-145 or PC3 prostate cancer cells with
15  M ACS2 or ACS33 caused hyperacetylation of histone H4,
and administration of 30  M ACS2 or ACS33 was sufficient to
induce elevation of histone H3 acetylation. Furthermore, micromo-
lar concentrations significantly prevented tumour cell growth in
vitro and stopped tumour cell adhesion to HUVEC. With respect to
this feature, ACS2 administered for 5 days was more potent than
a 3 day application, whereas ACS33, given for 5 days, was not
superior to the 3 day incubation period. It is not clear if these dif-
ferences are caused by a different passage time of the drugs
Fig. 4 ACS33 prevents destruction of the
endothelial cell monolayer induced by
prostate tumour cells. Morphological
analysis is shown. 4 hrs after adding DU-
145 or PC3 tumour cells to HUVEC, round
openings appear in the endothelial mono-
layer in the course of tumour cell binding
(arrows). Application of ACS33 prevents
focal disruptions of intercellular endothelial
connections (right hand; both: phase con-
trast,  20 objective).
Fig. 5 Western blot analysis of H3 and H4 histone expression (total and acetylated) in ACS-treated- and non-treated cells. DU-145 or PC3 cells were
incubated with ACS2 or ACS33 for 24 hrs. Cell lysates were then analysed by specific antibodies as listed in materials and methods.  -actin served as
the internal control. One representative experiment of three is shown. 2464 © 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 6 Effect of ACS33 on prostate cancer xenografts. PC3 xenografts were established in male athymic mice. Animals in the treatment arm received 20
mg/kg bw ACS33 each day, or 2 mg cisplatin/kg/day (cis-pt). *Indicates significant difference to the control animals. Western blot analysis of H3 and H4
histone expression (total and acetylated), of bcl-2, bax, ILK and Fak (total and activated) was carried out on the tissue specimens using specific antibod-
ies as listed in materials and methods (Fig. 6, right).  -actin served as the internal control. One representative western blot data of three are shown.
Fig. 7 Histological examination of the PC3
tumour xenografts growing s.c. in male
athymic mice. Representative pictures are
shown. Immunostaining of MIB (dark red
reaction product) documents a decreased
tumour cell proliferation. Enhanced
immunostaining of acetylated H3 indicates
HDAC-inhibitory activity of ACS33.J. Cell. Mol. Med. Vol 12, No 6A, 2008
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through the cellular membrane or by a different cellular response
towards both compounds. It has been demonstrated that long-
term application of VPA is necessary to delay tumour cell growth
and block metastatic processes [26, 27]. Xia et al. supposed that
chronic administration of VPA is required to achieve therapeutic
benefits [28]. This may also be the case for VPA-analogues.
Significant tumour reduction was not seen until 1 week after start-
ing chronic ACS33 application in the PC3 xenograft model. 
Concerning the animal data, 20 mg/kg ACS33 induced distinct
antitumoural activity in the xenograft model. This is 10-fold lower
than the optimum concentration of VPA required to exert similar
effects. Shabbeer et al. treated male nu/nu mice with 200 mg/kg bw
VPA daily to evoke significant growth blockade of xenografted
prostate tumour cells [21]. The same dosing schedule was recom-
mended by Xia and coworkers [28] and Gao et al. [29] to diminish
prostate cancer xenograft growth by 40–70%. We did not repeat the
same experiments; however, 200 mg/kg bw VPA was necessary to
significantly reduce the in vivo growth of kidney carcinoma cells
whereas 20 mg/kg bw VPA was without any effect (data not shown). 
No body weight loss or overt toxic effects in the treated ani-
mals, which could be related to the drug treatment, were
observed. Therefore, ACS33 seemed well tolerated and safe. Still,
this conclusion is made with caution since side effects in humans
may develop during protracted treatment. It is notable that our in
vivo data are based on the hormone-independent prostate tumour
cell line PC3, since it is the androgen-independent prostate cancer
that ultimately leads to patient death. Consequently, ACS2 and
ACS33 may become particularly important for patients with recur-
rent and progressive disease. 
The present investigation demonstrates that potent HDAC-
inhibitors can be derived from the VPA mother compound. Studies
which deal with structure-activity relationships of VPA are limited.
Based on a mouse model, it has been found that the  -carbon atom
of VPA must be tetrahydral (sp3 hybridization) and connected to a
free carboxyl function to express significant anti-tumoural potential
[9, 30]. Two alkyl groups, branched on the carbon atom C-2 are
also obligatory to evoke anti-tumoural effects [31]. However, 
structural modifications such as derivatization of the carboxylic
function, side chain elongation and further branching, introduction
of double and triple bonds and enantiomeric derivatives with the
chiral center at position C-2 allowed distinct modifications of the
pharmacokinetic profile of VPA. In particular, side chain elongation
of VPA derivatives with a triple bond in position C-4 resulted in
decreasing IC50-HDAC values, while further branching of one side
chain diminished the HDAC inhibition effect [9].
Lu and colleagues rationalized that the weak potency of VPA may
be, in part, attributable to its inability to access the Zn
2+ cation in the
HDAC active-site pocket, which plays a pivotal role in histone
deacetylation catalysis. Tethering VPA with Zn
2+-chelation via an
aromatic linker led to the development of novel compounds that
showed inhibition of HDAC activity and cancer cell proliferation in
the micromolar range. The finding that removing the valproyl group
completely abrogates the inhibitory activity of the conjugate under-
scored the importance of the acyl moiety in interacting with the
active-site pocket [32].
This is the first report that demonstrates potential anti-tumoural
effects of VPA-derivatives in a prostate cancer model. In vivo, west-
ern blot analysis and immunohistochemistry revealed an associa-
tion between ACS33-induced growth inhibition and intra-tumour
histone H3 acetylation. These pharmacodynamic data suggest that
ACS33, as administered, reached the molecular targets that are,
however, still not pinpointed. Aside from the direct biological effects
on tumour cells, an indirect mode of action should also be consid-
ered. We have previously reported that the mother compound, VPA,
modulates angiogenesis and tumour immunity [8, 33]. An anti-
angiogenetic activity has already been found for ACS2 [17].
From a clinical viewpoint, molecular-targeted therapies includ-
ing both HDAC and angiogenesis inhibition provide promise.
Further studies are necessary to understand the molecular back-
ground of post-transcriptional modifications and to design specific
VPA derivatives to exploit the potential of this class of agents in
the treatment of prostate cancer.
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